Analyst Reco. OKYO Pharma Limited

Equities

Delayed Nasdaq Other stock markets 18:08:54 20/05/2024 BST			5-day change	1st Jan Change
1.538 ^USD	+1.20%		+3.93%	-13.10%

03-22	H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	MT
03-22	OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101	CI

H.C. Wainwright Adjusts Price Target on OKYO Pharma to $7 From $6, Maintains Buy Rating	03-22	MT
HC Wainwright Initiates Coverage on OKYO Pharma with Buy Rating, $4 Price Target	11-02	MT

No results for this search